NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NGM Biopharmaceuticals, Inc
RS Oncology LLC
Ascentage Pharma Group Inc.
Infinity Pharmaceuticals, Inc.
Shenzhen BinDeBio Ltd.
Taxolog Inc.